Literature DB >> 9098681

EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties.

G D Bartoszyk1, R Hegenbart, H Ziegler.   

Abstract

The 5-HT1A receptor agonist 8-hydroxy-(di-n-propylamino)tetralin (8-OH-DPAT; 0.55 mg/kg s.c.) and the 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor/5-HT1A receptor ligand 5-[4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl]-benzofuran-2-carbox ami de (EMD 68843; 55 mg/kg p.o.) inhibited ultrasonic vocalization in rats, an effect which was antagonized by the 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl]-N-(2-pyridyl)- cyclohexancarboxamide (WAY 100635; 1.0 mg/kg s.c.). 8-OH-DPAT decreased body temperature in rats, an effect which was also antagonized by WAY 100635, whereas EMD 68843 neither affected body temperature by itself nor interacted with 8-OH-DPAT or WAY 100635. The selective 5-HT reuptake inhibitor fluoxetine (100 mg/kg p.o.) had no effect on ultrasonic vocalization or body temperature. Therefore EMD 68843 is suggested to be a 5-HT1A receptor agonist selective for presynaptic 5-HT1A receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9098681     DOI: 10.1016/s0014-2999(96)00999-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

Review 1.  The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.

Authors:  Eleni Pitsillou; Sarah M Bresnehan; Evan A Kagarakis; Stevano J Wijoyo; Julia Liang; Andrew Hung; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

Review 2.  ACS chemical neuroscience molecule spotlight on viibryd (Vilazodone).

Authors:  Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2011-10-19       Impact factor: 4.418

3.  Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.

Authors:  Christoph van Amsterdam; Christoph A Seyfried
Journal:  Psychopharmacology (Berl)       Date:  2014-01-14       Impact factor: 4.530

Review 4.  5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function.

Authors:  Alvaro L Garcia-Garcia; Adrian Newman-Tancredi; E David Leonardo
Journal:  Psychopharmacology (Berl)       Date:  2013-12-12       Impact factor: 4.530

Review 5.  Vilazodone: in major depressive disorder.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

Review 6.  Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

Authors:  Lee A Dawson; Jeannette M Watson
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

7.  Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor.

Authors:  Thomas L Schwartz; Umar A Siddiqui; Stephen M Stahl
Journal:  Ther Adv Psychopharmacol       Date:  2011-06

8.  Translatability scoring in drug development: eight case studies.

Authors:  Alexandra Wendler; Martin Wehling
Journal:  J Transl Med       Date:  2012-03-07       Impact factor: 5.531

Review 9.  Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy.

Authors:  David J Hellerstein; Joseph Flaxer
Journal:  Core Evid       Date:  2015-04-20

10.  Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma.

Authors:  Xi-Nan Shi; Hongjian Li; Hong Yao; Xu Liu; Ling Li; Kwong-Sak Leung; Hsiang-Fu Kung; Marie Chia-Mi Lin
Journal:  Mol Med Rep       Date:  2015-09-10       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.